Researchers sought to investigate diagnostic tools of acquired VWS compared with multimer analysis as diagnostic criterion standard.
Researchers sought to determine the role of the A1 domain of the VWF glycoprotein in VWF tubule assembly.
Researchers sought to determine whether rondoraptivon pegol would improve VWF and factor VIII levels in patients with type 2B von Willebrand disease.
Researchers sought to determine whether the VWF gene variant would be predictive of desmopressin response in patients with VWD.
Researchers sought to determine whether prophylaxis with recombinant VWF would lead to a decrease in annualized bleed rate in patients with VWD.
Researchers sought to determine whether long-term prophylaxis against bleeds in patients with von Willebrand disease would be cost effective.
Researchers sought to determine whether plasma-derived VWF would be effective in treating hemorrhage in young children with severe VWD.
Results showed the median ABR for all bleeds was reduced by 54.7%.
Researchers described a case study that suggested ibrutinib may have beneficial effects in patients with acquired von Willebrand syndrome that is secondary to Waldenström macroglobulinemia.
Researchers sought to determine whether the HemosIL VWF activity assay would be an effective method for identifying VWD.
